SKSertac Kucukkaya

Sertac Kucukkaya

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sertac Kucukkaya has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Identification of rare Candida species isolated from various clinical specimens: Comparison of different methods

    by Ilvana Caklovica Kucukkaya, Deniz Turan, Sertac Kucukkaya, Esma Akkoyun Bilgi, Enxhi Caglar, Gonca Erkose Genc, Zayre Erturan

    In recent years, there has been an increase in invasive infections caused by “'rare' Candida species”. The intrinsic resistance characteristics of these species along with their higher antifungal MIC values reduce the success of antifungal treatment. Although molecular and other sophisticated tests are reliable for the identification of many rare and newly emerging Candida species. Their implementation in routine laboratories is limited due to trained personnel, high costs, and specialized laboratory equipments. As a result, conventional methods and automated systems such as VITEK-2 and MALDI-TOF MS are still widely used in routine laboratories. This study evaluates and compares the identification capabilities of these commonly used tests for rare Candida species and provides guidance for rapid identification. A total of 201 isolates consist of 16 rare Candida species from various clinical samples were analyzed. Identification was performed using VITEK MS (as a gold standard) and results compared with VITEK-2, API ID 32 C, CHROMagar Candida, CHROMagar Candida Plus, and cornmeal agar with 1% Tween 80. VITEK MS identified all isolates and among them, the three most common species were Candida inconspicua (n:34; 16.9%), Candida lusitaniae (n:33; 16.4%), and Candida kefyr (n:31; 15.4%). Among these, a total of 107 isolates (53.2%) were correctly identified at the species level using the VITEK-2 system, whereas only 51 isolates (25.37%) were accurately identified with the API ID 32C system. However, when additional conventional methods (colony morphology and colour on chromogenic agar medium, Dalmau plate method, esculin hydrolysis test, growth at different temperatures) were applied, these identification rates increased to 81.5% (n = 164) and 54.7% (n = 110), respectively. Notably, even when used alone, the VITEK-2 system demonstrated a high identification success rate for Candida auris (83.3%), Candida lipolytica (85.7%), Candida lusitaniae (78.7%), Candida guilliermondii (83.8%), and Candida dubliniensis (86.4%). One of the primary reasons for misidentification was the absence of these microorganisms in the databases of the identification systems used. Additionally, all C. auris strains were correctly identified using CHROMagar Candida Plus medium, with no false-positive results observed for other Candida species. None of the identification methods, when applied alone, were able to correctly identify all 201 rare Candida species. Both VITEK-2 and API ID 32 C demonstrated limited accuracy for some rare species. However, evaluating microscopic and colony morphology on cornmeal agar and chromogenic media improved the accuracy of identification, especially for C. auris. In laboratories with limited access to MALDI-TOF MS or molecular methods, these tests should be used in combination to improve identification accuracy and provide alternative approaches for species differentiation. Also laboratories should update regular databases of their systems constantly. These organisms may be considered “rare” because they remain unidentified due to limitations in current identification methods and databases.


  • Open Access

    Evaluation of Blood Cultures from SARS-CoV-2-Positive and Negative Adult Patients

    by Bahar Akgün Karapınar, İlvana Çaklovica Küçükkaya, Yasemin Bölükbaşı, Sertaç Küçükkaya, Gonca Erköse Genç, Zayre Erturan, Ali Ağaçfidan, Betigül Öngen

    Bacteremia and fungemia are significant causes of morbidity and mortality that frequently occur as co-infections with viral respiratory infections, including SARS-CoV-2. The aim of this study was to evaluate the microorganisms that were isolated from the blood cultures of SARS-CoV-2-positive and negative patients and investigate their antimicrobial resistance patterns. A retrospective analysis was performed of 22,944 blood cultures sent to the laboratory between November 2020 and December 2021. Blood culture analyses were performed using the BD Bactec FX automated system. Identification was carried out using conventional methods, namely, VITEK-2 and MALDI-TOF MS. Antibacterial/antifungal susceptibility tests were performed according to EUCAST/CLSI recommendations. SARS-CoV-2 tests were performed with RT-PCR. Culture positivity was detected in 1630 samples from 652 patients. Of these 652 patients, 633 were tested for SARS-CoV-2; 118 (18.6%) were positive and 515 (81.3%) were negative. The bacteria and fungi that were isolated at the highest rate in SARS-CoV-2-positive patients were methicillin-resistant coagulase-negative staphylococci (MR-CoNS) (21.5%), Escherichia coli (12.4%), Klebsiella pneumoniae (12.4%), Candida albicans (1.65%), and Candida glabrata complex (1.65%), while in the negative patients, the highest rates were for E. coli (21.3%), MR-CoNS (13.5%), K. pneumoniae (12.05%), C. albicans (2.1%), Candida parapsilosis (1.1%), and Candida tropicalis (0.9%). No statistically significant difference was determined between COVID-19-positive and negative patients in terms of detection, such as with the Pseudomonas spp., Enterococcus spp., and methicillin-resistant Staphylococcus aureus isolated from the blood cultures (p > 0.05). The most common isolate was MR-CoNS in SARS-CoV-2-positive patients (p = 0.028). Acinetobacter baumannii was more frequent (p = 0.004) and carbapenem-resistant K. pneumoniae was isolated at a higher rate (60% vs. 43%) in SARS-CoV-2-positive patients compared to SARS-CoV-2-negative patients (p > 0.05). These findings highlight the fact that isolation procedures should not be disregarded and the distribution of bacterial/fungal agents of bloodstream infections and their antibiotic resistance should be followed up during a pandemic, such as in the case of COVID-19.